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Recently, attention in the field of bipolar disorder (BD) has focused on prevention, including early
detection and intervention, as these strategies have the potential to delay, lessen the severity, or even
prevent full-blown episodes of BD. Although knowledge of the neurobiology of BD has advanced sub-
stantially in the last two decades, most research was conducted with chronic patients. The objective of
this paper is to comprehensively review the literature regarding the early stages of BD, to explore
recent discoveries on the neurobiology of these stages, and to discuss implications for research and
clinical care. The following databases were searched: PubMed, PsycINFO, Cochrane Library, and
SciELO. Articles published in English from inception to December 2015 were retrieved. Several
research approaches were used, including examination of offspring studies, retrospective studies,
prospective studies of clinical high-risk populations, and exploration of the progression after the first
manic episode. Investigations with neuroimaging, cognition assessments, and biomarkers provide
promising (although not definitive) evidence of alterations in the neural substrate during the at-risk stage.
Research on BD should be expanded to encompass at-risk states and aligned with recent methodological
progress in neuroscience.
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Introduction
Bipolar disorder (BD) is a chronic, relapsing, and poten-
tially progressive disorder.1-3 Recently, a focus on preven-
tion, including early detection and intervention, has begun
to attract increasing attention, as such strategies have the
potential to delay, lessen the severity, prevent progression,
or even prevent full-blown BD.4,5 The notion that BD is
a condition that follows a reasonable, predictable course
across stages was a key aspect in developing proposals
for prevention and early intervention.6 Indeed, there are con-
sistent data suggesting that, at least for a large subgroup
of patients, BD actually follows a progressive course,
which can be observed both in clinical outcomes (such as
functional impairment) and in neurobiological findings
(such as structural brain damage).7,8
According to these models, the disorder starts during
the ‘‘at-risk period’’ and progresses from the first mood
episode through to late-stage disease, where symptoms
are more chronic, pervasive, and treatment-resistant, and
putatively caused by brain changes related to the action
of neurotoxic mediators and reduction of neurotrophic and
neuroprotective support.2,9 The progression of BD results
in increasing severity of clinical symptoms, cognitive impair-
ment, and functional deterioration, demanding more com-
plex and expensive treatment alternatives.2 From this
perspective, prevention of BD progression is paramount
to reducing the major economic, psychosocial, and func-
tional impact of this disorder on patients, families, and
societies.
Knowledge of the neurobiology of BD has advanced
substantially in the last two decades. Nevertheless, most
studies have been conducted with chronic (i.e., late-
stage) patients.10 Biomarkers seem to play an important
role in evaluating disease activity and progression asso-
ciated with different mood states (mood biomarkers), as
well as to identify specific characteristics of the disease
(trait biomarkers).11,12 The available evidence indicates
that neurotrophins, oxidative stress, and inflammation are
linked to the acute and euthymic phases of BD,13,14 and
indicate the presence of systemic toxicity.15
The use of clinical staging models is emerging as a
novel and useful paradigm to inform diagnosis and
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treatment of BD.16-18 Staging models and the concept of
neuroprogression represent significant advances in the
field and provide a new scientific base for early interven-
tion.7,19-21 The term neuroprogression has been increas-
ingly used to define the pathological reorganization of the
central nervous system (CNS) that occurs over the course
of severe mental disorders.12 This reorganization may
arise as the result of several ‘‘insults,’’ such as inflamma-
tion and oxidative stress.12 To refine clinical staging
models and identify novel, specific targets for early
intervention, it is essential to understand the pathophy-
siological processes associated with the clinical stages of
illness development.17,22 Indeed, there is convergent
evidence from longitudinal studies to support the hypoth-
esis that BD develops in a series of predictable clinical
stages in those at genetic risk.22,23
Nevertheless, few studies have approached the early
stages of BD, and data on potential neurobiological dif-
ferences between early- and late-stage BD are scarce.12
This is a notable contrast to the field of psychosis, in which
a large proportion of research resources has been targeted
at understanding, recognizing, and managing early-stage
disease.24-27
The objective of this article was to provide a compre-
hensive review of the literature on neurobiology of the early
stages of BD, with a special focus on the late prodromal
stage and the period surrounding the first episode of
mania. We also aimed to discuss the implications of
emerging research findings in this field for investigation
and clinical care.
Search strategy
A comprehensive literature search of computerized data-
bases (PubMed, PsycINFO, Cochrane Library, and
SciELO) was performed using the following terms: ‘‘bipolar
disorder,’’ ‘‘mania,’’ ‘‘manic-depressive illness’’ cross-refer-
enced with ‘‘prevention,’’ ‘‘early detection,’’ ‘‘early interven-
tion,’’ ‘‘bipolar at risk,’’ ‘‘prodromal,’’ ‘‘preclinical,’’ ‘‘at risk
mental states,’’ ‘‘clinical high risk,’’ ‘‘ultra-high risk,’’ ‘‘first
episode of mania,’’ ‘‘biomarkers,’’ ‘‘brain-derived neuro-
trophic factor,’’ ‘‘inflammation,’’ ‘‘cytokines,’’ ‘‘oxidative
stress.’’ Articles published from inception to December
2015 were retrieved. Selection of articles for inclusion in
the review was based primarily on the information available
in the study abstracts. The reference lists of the selected
articles were also hand-searched for additional, potentially
relevant citations. The exclusion criteria were articles
written in languages other than English and studies of
juvenile or pediatric BD (as we wished to focus on the adult
phenotype of BD).
Clinical presentation of early stages
The gradual evolution of BD has been well recognized by
individuals, their family members, and clinicians. In fact,
there are convergent findings in the literature from extensive
clinical observations regarding to the period of weeks, months,
or even years during which mild, intermittent, and sub-
threshold mood symptoms are present before the onset of
the first mood episode.28,29 Several studies have recognized
mood lability, major depressive episodes, subsyndromal
manic symptoms, a diagnosis of a bipolar spectrum disorder
(such as cyclothymia or BD not otherwise specified), and
mood-congruent psychotic symptoms as precursors of
BD.30-32 On the other hand, in clinical practice, identifica-
tion of a symptomatic high-risk BD phase is complicated
by the complex nature of dimensions of this disorder, by
potentially different symptom presentations in children
and adolescents,5,21,33 and by the blurred lines between
the prodrome and the disease itself.34
Retrospective and prospective studies have revealed
a pattern of putative prodromal symptoms, of which mood
lability/mood swings/cyclothymic features, depressive
mood, racing thoughts, irritability, and physical agitation
are most commonly reported.4,21 Considering that the
onset of first manic episode occurs mainly in adolescence
and early adulthood, it can be assumed that mild, poorly
differentiated, or nonspecific symptoms influence the
earliest developmental stages of the individual.35,36 In
fact, retrospective studies have shown that BD patients
may report symptoms as early as 2 years of age, even
though these manifestations are highly unspecific (such
as sleep disorders or excessive crying).37-39 Over time,
with the progression of psychopathology across personal
developmental phases (childhood, puberty, adolescence,
etc.), there is a trend for symptoms to become more
specific and more similar to BD.40 Accordingly, a 4-year
follow-up study found that 38% of children and adoles-
cents initially diagnosed with subsyndromal symptoms of
BD (usually cyclothymia and BD not otherwise specified)
and 25% of those diagnosed with type II BD were
ultimately diagnosed with type I BD during the follow-up
period.41
Study designs for the early stages of BD
Offspring studies
BD is a highly heritable disorder, with up to 85% of the
variance in risk determined by genetic factors; hence,
a positive family history is still the best predictive factor
for development of the illness.18,22,23 However, a family
history does not merely predict an increased risk of BD.
Meta-analyses have shown that, compared to other
children, the offspring of a BD parent (OSBP) have an
eight- to tenfold increase in lifetime risk of developing BD,
but also a threefold lifetime risk of any severe mental
disorder (e.g., psychosis) and one-in-two odds for any
mental disorder.42 Thus, OSBP studies provide a reliable
and valid means for identifying a sample of individuals at
high risk of developing mental disorders, and can provide
information on prodromal signs and symptoms of BD
and rates of transition from ‘‘at-risk’’ state to clinical
‘‘caseness.’’43 Importantly, the study of OSBP is a useful
‘‘enrichment’’ strategy that may help identify the under-
lying pathophysiology and evolution of clinical stages
of BD over time and access factors such as potential
interactions between genetic liability, birth weight, and
early-life stress.44,45
In addition, studies of OSBP can enhance our under-
standing of the clinical phenotypes of individuals at high
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risk of developing BD and demonstrate the heterotypic
continuity of problems with a common developmental
pattern, involving, e.g., anxiety problems in childhood, a
first mood episode in early adolescence, and a (hypo)
manic episode in late adolescence or early adult-
hood.22,23 Prospective studies have the potential to clarify
the illness trajectory by exposing the temporal relationship
between childhood difficulties or non-mood problems
and later affective pathology or development of BD. Ques-
tions as to whether non-mood pathology represents
a risk syndrome or earlier manifestation of the disorder
or whether it is a concurrent disorder in its own right
may be answered by such studies of high-risk children.
Furthermore, the longitudinal follow-up of affected and
unaffected high-risk siblings from an early age allows
exploration of clinical, biological, and environmental factors
that may predict which high-risk family members ulti-
mately develop BD.46
However, when reviewing the findings on neurobiology
and staging that derive from OSBP studies, it is important
to consider differences in methodology.47 There are
often differences in the sampling or recruitment strategy
employed (clinical/community; offspring of one affected
parent/two affected parents), the assessments used
(self/observer-rated), and the timeframe of assessment
(cross-sectional/longitudinal; retrospective/prospective).
The methods employed to recruit families into OSBP studies
also vary widely, and include recruitment of families
already involved in neurobiological and genetic research
projects,48 recruitment of all or some participants via self-
referral and/or advertising campaigns,49 recruitment
from hospital settings and specialized clinics,50 and from
patient advocacy associations.44 Notably, higher rates of
comorbidity are evident in studies that recruit via self-
referral and families where the non-proband parent also
had a non-affective psychiatric illness. Likewise, the
nature of the control group also influences findings. For
example, studies which included healthy children as
controls demonstrated a major increase in a range of
psychopathology in the OSBP, while studies using
children of chronically medically ill parents (so-called
positive controls) often show high levels of psychopathol-
ogy in the comparison group as well as in the OSBP
group.51 Finally, the use of pediatric or adult diagnostic
criteria to identify BD, and the use of dimensional rather
than categorical measures of psychopathology, may
influence study findings.46 These issues are highly
relevant to any comparisons of data regarding neurobiol-
ogy of the stages of BD, as heterogeneity in OSBP clinical
phenotypes or illness trajectories may obscure rather than
clarify our understanding of clinicopathological bound-
aries across illness stages.
Retrospective designs
The majority of studies investigating the prodrome of BD
have used retrospective designs.3 These studies sup-
port the existence of a prolonged, symptomatic prodrome
prior to the first episode of BD.52 Symptoms reported
retrospectively during the prodromal phase include both
mood (depressive symptoms, manic symptoms, mood
lability, cyclothymia) and non-mood features (such as
anxiety, sleep and concentration problems, and energy
changes).53
Retrospective studies of the BD prodrome have used
a variety of methods to assess data from patients and
caregivers, thus limiting comparison across studies.52
Most used either unstructured questionnaires or chart
reviews, and failed to assess the onset pattern of the
disorder and the symptom severity of the prodromal
period, which limits validity.5 Furthermore, it remains
unclear which person (i.e., the patient, a parent, teacher,
or peer) is most likely to first notice the prodromal
symptoms.5 Thus, studies that access information regard-
ing prodromal symptoms only from the point of view of
patients themselves may be less reliable. Finally, recall
bias is another limitation that must be taken into account
when analyzing findings on neurobiology derived from
retrospective studies.53
Prospective studies of first-episode mania
Prospective studies of first-episode mania are crucial
to improving our understanding of the development,
onset, and progression of BD. This strategy allows us
to identify clinical correlates that might characterize
patients at risk of poor medium- to long-term outcomes,
and avoids the confounding effects of multiple episodes,
morbidity, comorbidities, and treatment.54,55 Additionally,
this approach may help optimize treatment planning for
the clinical, cognitive, and functional characteristics of
patients identified as being at different, distinct stages of
the illness.56
Different methodologies have been used in first-episode
studies, and this must be taken into account when inter-
preting results from such investigations.57-59 For instance,
there is a lack of homogeneity regarding the definition of
first mood episode. Follow-up studies have included
patients with different mood states (mania, mixed states,
or BD depression); included mixed samples of patients
with BD and psychosis; or have defined first-episode
onset as the first hospitalization.57,59 The mean age of the
BD sample is another limitation in some studies. In our
review of the literature, it is notable that most first-episode
BD studies were conducted in adults60,61 and very few
included children or adolescents.62,63 The nature of the
control groups used in these first-episode studies is also
a topic of some debate.59,64 Findings that emerge from
studies comparing BD cases with healthy controls or
probands to their relatives have shown consistent
differences in regard to cognition. However, the magni-
tude of these differences in cognitive functioning itself
differs according to the choice of control group. Overall,
when compared to healthy controls, BD cases demon-
strate more overt cognitive impairment, whereas smaller
differences in cognitive performance have been observed
when BD cases are compared to healthy relatives.59
This may point to methodological issues, or may repre-
sent a genuine link between a clinical phenotype and
an inherited endophenotype.65 However, disentangling
these issues is complex, as even first-episode studies
include many patients on polypharmacotherapy, and the
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possible triggering effect of these drugs has not been
considered.57,59
Prospective studies of individuals at clinical risk of BD
Prospective studies of individuals at risk of BD present
a potentially reliable and valid approach to understanding
the progression of BD psychopathology.4,66 Many studies
use enrichment strategies to enhance the possibility of
studying a sample in which a large proportion of subjects
experience onset of BD. However, the disadvantage of this
approach is that it may limit the universality of findings, due
to lack of power or specificity for predicting BD as com-
pared to onset of a range of mental disorders.53 High-risk
prospective studies investigate individuals that are at
specific risk of developing BD due to genetic loading or
presence of early manifestations of psychiatric symptoms
at a subclinical level,53 in the so-called close-in strategy.21
Research into the prodromal phase of BD has led to
the assumption that individuals presenting at preclinical
stages of BD may be identified. Initially, ultra-high risk
(UHR) or bipolar at-risk (BAR) criteria for BD have been
proposed, assuming that the initial phases of the disease
may present with symptoms that are insufficient in severity,
frequency, or duration. These criteria include: (a) subthre-
shold mania; (b) depression with cyclothymic features;
or (c) depression associated with genetic risk for BD.67
Recently, the BAR criteria were validated in a prospective
study of adolescents and young adults. In the BAR group,
14.3% converted to first-episode hypomania/mania (as
opposed to none in the control group) at 1-year follow-up,
with subthreshold mania having the greatest predictive
value.4 In future, strategies to identify at-risk individuals
will be partly dependent on the development of measure-
ment scales with robust psychometric characteristics,
such as the recently validated Bipolar Prodrome Symp-
tom Interview and Scale-Prospective.3
Neurobiology of the early stages of BD
Neuroimaging
Neuroimaging investigations of structural and functional
brain abnormalities in individuals at genetic risk of BD offer
several advantages: identifying brain abnormalities that
potentially predate the onset of BD and are not confounded
by factors such as illness duration or medication; identify-
ing brain abnormalities that may confer risk for or protect
against BD, to inform evaluation of risk of BD development
and subsequent therapeutic intervention; and improving
understanding of the developmental course of BD.68 Further-
more, neuroimaging abnormalities found in individuals
at high genetic risk may underlie the modest neuro-
cognitive impairments (namely, executive function and
working memory deficits) observed in relatives of patients
with BD.68
A number of imaging studies in individuals at genetic
risk for BD are available, including functional magnetic
resonance imaging (fMRI), positron emission tomography
(PET), magnetic resonance spectroscopy (MRS), diffusion
tensor imaging (DTI), and structural magnetic resonance
imaging (MRI) studies, which investigate grey- or white-
matter volumes. Despite this large volume of published
research, findings have been inconsistent, and no reliable
structural or functional markers of genetic liability to BD have
been identified.68 An advantage of neuroimaging studies
of young patients with BD is that they may help clarify
neurodevelopmental aspects of the illness and identify
biomarkers of disease onset and progression.68 Brain
imaging techniques such as MRI, PET, and DTI are
being used increasingly for direct quantification of neural
system abnormalities associated with BD and high risk
of BD.68
Neuroimaging techniques are also some of the most
powerful tools available for identification of endopheno-
types. Identifying endophenotypic markers would help to
confirm a likely diagnosis of BD; could allow clinicians and
researchers to discriminate BD depression from unipolar
depression; and, potentially, enable identification of at-
risk individuals who will subsequently develop the illness,
thus facilitating early intervention.68,69 Relevant findings
in BD to date have centered on functional and structural
neuroimaging studies, underlying core domains of the
pathology in children with BD and those at high risk.68,69
As new protocols, techniques, and technologies emerge,
there is the possibility of addressing important clinical
questions, including the identification of treatment-
relevant endophenotypes to create treatment response
groupings to meet the long-term goal of rational treatment
advances for BD.68,69
A recent meta-analysis showed that grey-matter loss
may be a state-related factor for BD, suggesting that
structural imaging may be a useful biomarker to distin-
guish individuals who will transition to BD from those who
will not.69 However, prospective studies of grey-matter
volume in high-risk individuals are needed to evaluate this
finding.69 The same meta-analysis found that hyper-
activation in the frontal and insular cortex is the neural
substrate for the executive function impairments seen
in high-risk individuals and patients with BD.69 The
similarity between these findings in high-risk individuals
and previous findings in patients with BD suggests that
hyperactivation in these regions is a good candidate
trait endophenotype for BD.69 However, further work is
needed to determine how this relates to the affective
disturbances and other clinical features that develop with
onset of BD.69
To date, most studies of white-matter changes in BD
have been conducted in older subjects and those with well-
established disorders.70 A recent study reported significant
changes in major white-matter tracts in a large cohort
of young patients in the early stages of BD.70 Specifically,
this study provided evidence of microstructural white-
matter changes within the corpus callosum early in the
course of illness.70 The nature of these changes suggests
an association with abnormalities in axon myelination.70
Collectively, these results are consistent with the notion
that BD is associated with discernable abnormalities in
white-matter integrity, and that this is driven predominantly
by the BD I phenotype.70
Another recent study that assessed white-matter micro-
structure and grey-matter volumes in a community
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sample of adolescents with BD found widespread altera-
tions in white matter involving a number of tracts that
continue to mature during adolescence.71 In addition, the
authors observed that BD in adolescents is associated
with structural connectivity alterations likely to affect the
development of white-matter bundles and connected
grey-matter areas involved in emotion regulation.71
Since patients with BD have been reported to show
hippocampal abnormalities, a recent systematic review of
25 studies analyzed hippocampal volume.72 The results
were consistent with decrease in hippocampal volume
in four of 18 studies using adult samples and two of
three samples using adolescents. Four studies revealed
localized hippocampal deficits.72 Meta-analysis revealed
a significant but small effect with lower hippocampal
volumes when comparing all BD patients vs. controls.72
Lithium treatment was associated with larger hippocam-
pal volumes across studies. Three functional studies were
included and yielded contradictory evidence; the authors
concluded that BD seems to feature a minor reduction
in hippocampal volume, which may be more pronounced
in early-onset BD and counteracted by a neuroprotec-
tive effect of lithium treatment.72 However, how these
structural abnormalities relate to functional deficits is
largely unclear.72 Given the paucity of functional neuroi-
maging studies and lack of congruence in their results,
further investigation of hippocampal function in BD is
recommended.72
The Systematic Treatment Optimization Program for
Early Mania (STOP-BD) study used single-voxel proton
MRS to assess hippocampal neurometabolite levels in
patients with BD recruited within 3 months of recovery
from first manic episode. In this study, glutamate plus
glutamine (Glx) and N-acetyl aspartate levels were no
different between BD patients and matched healthy
subjects at baseline, and levels did not change differen-
tially during the 1-year follow-up period in BD patients
compared with controls. This suggests that patients in
the early stage of BD did not experience alterations in
hippocampal neurochemistry, and supports the impor-
tance of early interventions to arrest illness progression
in BD.73
In summary, translating knowledge of the neuroanat-
omy of BD into a diagnostic tool or test paradigm will
require identifying the neural signature of predisposition
for BD (potential cause) and separating it from the effects
of long-standing illness and treatment (possible conse-
quence of the disease process).74 Finally, structural
neuroimaging studies focusing on volume could aid in
the identification of individuals at risk of BD even before
any behavioral manifestation, and further research into
associations among genetic risk, illness burden, lithium
treatment, and brain structure in BD could be useful.74
Neurocognition
There is mounting evidence that individuals with BD
experience neurocognitive deficits even in remission
periods.65,75,76 This may be explained, in part, by the pro-
gressive course of illness involving relapses with increas-
ing severity of residual symptoms, comorbidity with other
psychiatric and medical conditions, and adverse effects
of treatment. However, whether these cognitive deficits
occur early in the course of BD or predate the onset of the
diagnosable mood disorder is not yet clear.
Distinct methodologies have been used to investigate
cognitive function in the premorbid stage of BD, both in
general population studies (e.g., conscripts to national
service or community-based cohorts) and in clinical high-
risk or genetic studies of BD.59,66 For instance, three
‘‘conscript’’ studies included young adults recruited from
the armed forces and followed these individuals prospec-
tively over long periods, but provided inconsistent or
inconclusive findings.77-79 Zammit et al.79 suggested that
individuals who developed BD had cognitive performance
comparable to that of healthy controls, while Tiihonen
et al.78 showed that individuals who developed BD had
superior performance in arithmetic but poorer visuospatial
reasoning than healthy controls.
Another way to investigate neurocognitive functioning is
to examine individuals at high risk of mood disorders/
psychoses who are prospectively diagnosed as having BD.
Using this methodology, Meyer et al. found comparable
premorbid intelligence quotient (IQ) values between BD
offspring and controls, while poorer executive function
was observed among subjects who developed BD.80
In contrast, Olveta et al., in a follow-up study involving
adolescents at high risk of developing psychoses, reported
no differences in premorbid IQ or global neurocognitive
scores between subjects who developed BD and those
who did not transition to psychiatric illness.81 More
recently, Ratheesh et al.66 investigated young people at
UHR of psychoses during the prodromal phase of the
illness and followed them prospectively for approximately
8 years. Most cognitive measures did not differ between
subjects who developed BD and those who did not
transition to psychoses or BD.82 Subjects also showed
appropriate cognitive function (e.g., visual information
processing) before the onset of BD.
Assessment of cognitive functioning from the first epi-
sode of mania is important to better understand whether
cognitive deficits are already present at the early stages
of illness or are progressive. To date, we have identified
three meta-analyses that examined cognitive function-
ing in patients in first-episode mania.57-59 Lee et al.59
included 12 studies of cognition involving young adults
(mean age, 28.2 years) with first-episode mania or
mixed states, depression, or psychoses. Greater cogni-
tive impairment (with a modest effect size) was found in
patients compared to controls across eight domains,
except for visual learning and memory. These cognitive
dysfunctions were independent of current mood state,
with the exception of response inhibition, which was found
only in symptomatic patients. Similarly, Daglas et al.57
investigated the cognitive profiles of adults and adoles-
cents during the acute phase of mania and the period
following symptomatic recovery. The findings of this
meta-analysis were inconclusive, although individual
studies have previously reported cognitive dysfunctions in
specific domains during the asymptomatic period. More
recently, Trota et al.58 reported data from a meta-analysis
that compared global intellectual functioning measured
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before or following illness onset in psychiatric patients and
controls. Interestingly, individuals with BD demonstrated
poorer premorbid intellectual function than controls when
function was measured retrospectively, but not when
measured prospectively; BD cases also exhibited mod-
erate cognitive impairment after onset of illness. A 1-year
follow-up study in first-episode BD showed that cases
differed from controls with regard to specific cognitive
domains, such as processing speed, executive function,
verbal and nonverbal memory, and working memory.
Moreover, cognitive improvement (processing speed and
executive function) was observed in patients after 1 year
of follow-up, particularly in those without a history of
substance abuse and who had discontinued antipsychotic
treatment.55
Comparing results from studies of first-episode mania to
those of BD cases with multiple episodes, Lopez-Jaramillo
et al.60 observed worse cognitive performance (attention,
processing speed, and executive function) in euthymic
patients who had experienced at least three manic epi-
sodes as compared with patients who had only one prior
BD episode. Other researchers have also demonstrated
that patients who have had multiple episodes are more
likely to present with deficits in executive function and
verbal memory than those at early stages of BD.62,83
Furthermore, cognitive deficits may also limit long-term
psychosocial functioning, which means that patients with
greater cognitive impairment are more likely to experience
poorer outcomes. In this regard, we previously reported
progressive functional decline from the early through
late stages of BD.84 These findings are consistent
with previous studies indicating an association between
cognitive deficit and BD severity.62,85 The number of
manic episodes is strongly associated with cognitive
impairment,60,86 while other clinical features, such as
subsyndromal depressive symptoms,75 illness duration,87
psychotic symptoms,87 number of hospitalizations,85
psychiatric comorbidities,55,87 medications,6,55 and adher-
ence,87 have also been shown to correlate significantly
with cognitive impairment.
In short, early intervention could play a crucial role
in preventing illness progression (and any associated
cognitive/functional decline) in BD. Primary prevention
could be used to treat individuals at UHR of developing
psychiatric disorders, as well as patients in stage I (more
specific but still subsyndromal symptoms).88 There is
evidence supporting the neuroprotective benefits of early
interventions for stage I patients, with the possibility of
preserving cognitive and psychosocial functioning.76,89,90
Biomarkers
As several different sets of symptoms and risk factors
might be present prior to full-blown BD, a cluster of
features including trait factors (such as genetic risk and
personality traits) and state-related factors (such as
subthreshold symptoms) might best capture the ‘‘at-risk’’
state for BD.4 Moreover, correlating these symptoms with
prodromal biomarkers offers an exciting juncture whereby
targeted interventions could be opportunistically employed
to prevent neurodegenerative changes from accruing as
the disease progresses.11,91 Nevertheless, empirical data
supporting the use of biomarkers for outcome prediction in
prodromal stages are limited.92 One of the first studies,
conducted by Padmos et al.,93 identified a discriminating
and coherent expression of 19 pro-inflammatory genes
transcription in monocytes of patients with BD and in the
offspring of BD parents. These results were in line with the
work of Mesman et al.,23 who conducted a longitudinal
follow-up study and found that, during adolescence,
offspring of BD parents demonstrated increased inflam-
matory gene expression in monocytes, high serum levels
of pentraxin 3 (PTX3; a regulator of inflammatory res-
ponse), but normal levels of the chemokine CCL2,23 as
well as decreased levels of brain-derived neurotrophic
factor (BDNF). During young adulthood, monocyte activa-
tion remained, although to a lesser degree; serum PTX3
levels remained high; and signs of monocyte migration
became apparent through increased CCL2 levels. In
adulthood, circulating monocytes had lost their activation
state, but CCL2 levels remained increased, and both
BDNF and S100B were increased. These abnormalities
were independent of psychopathology state at all stages.
The identification of biological markers associated
with clinical symptoms of imminent mania onset (in clinical
high-risk individuals) might help increase the odds of
early detection of BD and allow selection of subgroups
for implementation of prevention strategies.5 To date, only
preliminary data about biomarkers in at-risk states are
available. These indicate that individuals at high risk of
developing BD may have higher levels of lipid peroxida-
tion as compared with healthy controls and lower levels
compared with young people with syndromal BD.94 In
addition, small-scale studies have suggested that changes
in sleep, circadian rhythm, and social rhythm regularity
are altered in at-risk youths compared with age- and
gender-matched healthy controls.95-97 The predictive power
of these biomarkers for transition to BD at follow-up is
unknown.9
Conclusions
This review highlights not only the emerging evidence but
also the critical gaps in our knowledge about the early
stages of BD. One of these gaps is the urgent need to
develop consensus-based criteria to define at-risk or
clinical high-risk states. It is also important to harmonize
recruitment criteria for offspring studies or, at least, to
mandate reporting of the sampling strategy employed,
thus allowing readers to compare the influence of
recruitment on outcomes. The current use of disparate
criteria makes if difficult to compare findings across
studies and to generalize findings to other locations
or to clinical practice. Incorporation of biomarkers into
research on the early stages of BD is also a necessity, as
clinical phenotypes alone are highly unlikely to have
predictive validity for BD onset. However, research on
biomarkers in psychiatry in general is still in its infancy
and beset by methodological issues, including reproduci-
bility, replication, validity, and integration concerns.92,98,99
Another challenge in predicting outcomes is the need to
develop and apply big-data bioinformatics platforms to
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analyze and integrate the volume of data available from
large samples, multiple samples, and international multi-
center studies.100 Bioinformatics tools allied to system
biology paradigms may support more robust discoveries
on the early stages of BD than any single approach on its
own.101
Despite gaps in our knowledge, it is still vital to raise
awareness among mental health professionals of the need
for more timely and accurate diagnosis of BD, so as to
enable recognition of the putative prodromes of BD as
early as possible and, consequently, to minimize the use
of antidepressant or psychostimulant monotherapies in
at-risk individuals. This has been an important first step in
promoting the philosophy of early intervention in psychosis,
and is equally important for the field of mood disorders.21,30
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